Scientific Reference
CJC-1295 +DAC
Two products share the CJC-1295 name, and the difference between them is a single chemical feature. This page covers the version carrying a drug affinity complex (DAC): a modified GHRH(1-29) backbone with a reactive linker, built around a maleimide group on the C-terminal lysine, designed to attach covalently to proteins in blood. Because of that, the peptide effectively becomes part of a plasma protein conjugate and behaves more like a protein than an ordinary short peptide, with a duration measured in days instead of minutes. Published human data are limited to a few early studies in healthy adults; analytical chemistry papers, including recent anti-doping work on detecting the conjugate, now make up a good share of the recent record.
Mechanism of Action
The active part is the same GHRH analogue: it is reported to bind the GHRH receptor on anterior pituitary somatotrophs, a Gs-coupled class B GPCR, raising cAMP and prompting growth hormone release, with IGF-1 following. What the DAC changes is exposure. Its linker crosslinks to free cysteine residues on plasma proteins, which both prolongs circulation and makes continuous receptor occupancy possible instead of the brief pulses native GHRH produces. Researchers ask what that sustained stimulation does to normal pulsatile secretion and receptor responsiveness; data are sparse.
Molecular Information
- Type: GHRH analogue with drug affinity complex (DAC)